Morepen starts commercial supplies under Rs 825 crore CDMO mandate
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories has begun commercial supplies under its Rs 825 crore CDMO mandate. The first dispatch of about Rs 50 crore was completed in Q1FY2026-27, moving the program from validation to commercial execution. Additional supplies of around Rs 225 crore are expected in Q2FY2026-27, subject to customer and regulatory schedules. Reactor capacity will scale to about 600 KL by end of Q2, followed by 800 KL and 1000 KL in later phases. The company is positioning itself as a scalable CDMO platform for long-duration global manufacturing partnerships.
Positive for shareholders as commercial revenue kicks in from a large Rs 825 crore contract, with Rs 275 crore of supplies expected within two quarters.